ArticleInternational journal of nanomedicine2012
Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles.
Article in International journal of nanomedicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 203 citations in OpenAlex.
- Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease.International journal of nanomedicine · 2015Pooled it
- Acupoint-administered sinapine thiocyanate-loaded dissolvable microneedles for bronchial asthma: dose-response relationship and PI3K/AKT signaling pathway-based mechanism.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Pulmonary Drug Delivery in the Era of Nanomedicine: From Biological Barriers to Artificial Intelligence-Driven Optimization.Pharmaceuticals (Basel, Switzerland) · 2026Review
- 3D-Bioprinted Hydrogels Based on Calcium Alginate and Turmeric (ACS omega · 2026Article
- Smart nanoparticle delivery systems for curcumin: a targeted strategy to enhance anticancer efficacy and bioavailability.Journal of materials science. Materials in medicine · 2026Review
- Therapeutic effects ofAvicenna journal of phytomedicine · 2026Article
- Lipid-Based Nanocarriers for Curcumin Delivery: A Promising Strategy in The Management of Inflammatory Diseases.International journal of nanomedicine · 2026Review
- Curcumin as a promising therapeutic agent for diabetic neuropathy: from molecular mechanisms to functional recovery.Diabetology & metabolic syndrome · 2025Review
- Treatment of lung diseasesMaterials today. Bio · 2025Review
- Targeting respiratory virus-induced reactive oxygen species in airways diseases.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Current State of Scientific Knowledge on Curcumin Encapsulation and Applications.Recent advances in food, nutrition & agriculture · 2025Review
- Current State of Scientific Knowledge on Curcumin Encapsulation and Applications.Recent advances in food, nutrition & agriculture · 2025Review
- Article
- Modified Ce/Zr-MOF Nanoparticles Loaded with Curcumin for Alzheimer's Disease via Multifunctional Modulation.International journal of nanomedicine · 2024Article
- Physico-chemical properties of curcumin nanoparticles and its efficacy against Ehrlich ascites carcinoma.Scientific reports · 2023Article
- Nanocarrier-mediated curcumin delivery: An adjuvant strategy for CNS disease treatment.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Recent Advances in Nanomaterials for Asthma Treatment.International journal of molecular sciences · 2022Review
- Formulation of Solid Lipid Nanoparticles Loaded with Nociceptin/Orphanin FQ (N/OFQ) and Characterization in a Murine Model of Airway Hyperresponsiveness.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Present scenarios and future prospects of herbal nanomedicine for antifungal therapy.Journal of drug delivery science and technology · 2022Review
- How Curcumin Targets Inflammatory Mediators in Diabetes: Therapeutic Insights and Possible Solutions.Molecules (Basel, Switzerland) · 2022Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Curcumin has shown considerable pharmacological activity, including anti-inflammatory, but its poor bioavailability and rapid metabolization have limited its application. The purpose of the present study was to formulate curcumin-solid lipid nanoparticles (curcumin-SLNs) to improve its therapeutic efficacy in an ovalbumin (OVA)-induced allergic rat model of asthma. A solvent injection method was used to prepare the curcumin-SLNs. Physiochemical properties of curcumin-SLNs were characterized, and release experiments were performed in vitro. The pharmacokinetics in tissue distribution was studied in mice, and the therapeutic effect of the formulation was evaluated in the model. The prepared formulation showed an average size of 190 nm with a zeta potential value of -20.7 mV and 75% drug entrapment efficiency. X-ray diffraction analysis revealed the amorphous nature of the encapsulated curcumin. The release profile of curcumin-SLNs was an initial burst followed by sustained release. The curcumin concentrations in plasma suspension were significantly higher than those obtained with curcumin alone. Following administration of the curcumin-SLNs, all the tissue concentrations of curcumin increased, especially in lung and liver. In the animal model of asthma, curcumin-SLNs effectively suppressed airway hyperresponsiveness and inflammatory cell infiltration and also significantly inhibited the expression of T-helper-2-type cytokines, such as interleukin-4 and interleukin-13, in bronchoalveolar lavage fluid compared to the asthma group and curcumin-treated group. These observations implied that curcumin-SLNs could be a promising candidate for asthma therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.